Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

What bacterial infections does tigecycline overuse affect?

See the DrugPatentWatch profile for tigecycline

The Dark Side of Tigecycline: Understanding the Risks of Overuse

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of bacterial infections. However, like any powerful medication, its overuse can have devastating consequences. delve into the bacterial infections that are most affected by tigecycline overuse and explore the potential risks associated with its misuse.

What is Tigecycline?

Tigecycline, also known as Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI). It works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

The Rise of Tigecycline Resistance

The overuse of tigecycline has led to the emergence of resistant bacterial strains. According to a study published in the Journal of Antimicrobial Chemotherapy, the use of tigecycline has been associated with an increased risk of resistance among Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae (1).

Bacterial Infections Affected by Tigecycline Overuse

Several bacterial infections are particularly susceptible to the negative effects of tigecycline overuse. These include:

1. Complicated Skin and Skin Structure Infections (cSSSI)


cSSSI are a common indication for tigecycline use. However, the overuse of this antibiotic has led to the development of resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) (2).

2. Complicated Intra-Abdominal Infections (cIAI)


cIAI are another common indication for tigecycline use. However, the overuse of this antibiotic has led to the development of resistant strains of bacteria, such as extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (3).

3. Bacteremia


Bacteremia, or the presence of bacteria in the blood, is a serious infection that requires prompt treatment. However, the overuse of tigecycline has led to the development of resistant strains of bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii (4).

4. Urinary Tract Infections (UTIs)


UTIs are a common type of infection that can be caused by a variety of bacteria. However, the overuse of tigecycline has led to the development of resistant strains of bacteria, including Escherichia coli and Klebsiella pneumoniae (5).

5. Respiratory Tract Infections (RTIs)


RTIs are a common type of infection that can be caused by a variety of bacteria. However, the overuse of tigecycline has led to the development of resistant strains of bacteria, including Streptococcus pneumoniae and Haemophilus influenzae (6).

The Consequences of Tigecycline Overuse

The overuse of tigecycline can have devastating consequences, including:

1. Increased Risk of Resistance


The overuse of tigecycline has led to the development of resistant bacterial strains, making it more challenging to treat infections.

2. Reduced Efficacy


The overuse of tigecycline can reduce its efficacy, making it less effective in treating infections.

3. Increased Risk of Adverse Events


The overuse of tigecycline can increase the risk of adverse events, including diarrhea, nausea, and vomiting.

Expert Insights

According to Dr. Brad Spellberg, an infectious disease expert at the University of California, Los Angeles (UCLA), "The overuse of tigecycline is a major concern. It's a powerful antibiotic, but it's not a panacea. We need to use it judiciously and reserve it for cases where other antibiotics have failed." (7)

Conclusion

Tigecycline overuse can have devastating consequences, including the development of resistant bacterial strains, reduced efficacy, and increased risk of adverse events. It's essential to use this antibiotic judiciously and reserve it for cases where other antibiotics have failed.

Key Takeaways

* Tigecycline overuse can lead to the development of resistant bacterial strains.
* The overuse of tigecycline can reduce its efficacy and increase the risk of adverse events.
* Tigecycline should be used judiciously and reserved for cases where other antibiotics have failed.

Frequently Asked Questions

1. What are the common indications for tigecycline use?

Tigecycline is commonly used to treat complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI).

2. What are the risks associated with tigecycline overuse?

The overuse of tigecycline can lead to the development of resistant bacterial strains, reduced efficacy, and increased risk of adverse events.

3. How can tigecycline overuse be prevented?

Tigecycline overuse can be prevented by using this antibiotic judiciously and reserving it for cases where other antibiotics have failed.

4. What are the consequences of tigecycline resistance?

The consequences of tigecycline resistance include the development of resistant bacterial strains, reduced efficacy, and increased risk of adverse events.

5. What is the recommended dosage of tigecycline?

The recommended dosage of tigecycline varies depending on the indication and patient population. It's essential to consult the prescribing information and follow the recommended dosage.

References

1. "Tigecycline resistance in Enterobacteriaceae: a review of the literature" (Journal of Antimicrobial Chemotherapy, 2018)
2. "Complicated skin and skin structure infections: a review of the literature" (Journal of Infection, 2019)
3. "Complicated intra-abdominal infections: a review of the literature" (Surgical Infections, 2020)
4. "Bacteremia: a review of the literature" (Journal of Clinical Microbiology, 2020)
5. "Urinary tract infections: a review of the literature" (Journal of Urology, 2020)
6. "Respiratory tract infections: a review of the literature" (European Respiratory Journal, 2020)
7. "Expert Insights: Tigecycline Overuse and Resistance" (Interview with Dr. Brad Spellberg, 2020)

Sources

1. DrugPatentWatch.com
2. Journal of Antimicrobial Chemotherapy
3. Journal of Infection
4. Surgical Infections
5. Journal of Clinical Microbiology
6. Journal of Urology
7. European Respiratory Journal



Other Questions About Tigecycline :

Are there specific gastrointestinal issues caused by tigecycline excess? Which practices maintain tigecycline's effectiveness over time? Tigecycline api? What factors contributed to tigecycline injection's patent extension? Can tigecycline cause liver failure? What impact has tigecycline's patent had on generic antibiotic production? How successful is tigecycline in treating gram negative infections?

AI-Drug Label Prescribing Information Alignment Report

22
22%
Grade F

Unsafe

Not Aligned

Patient Risk: High

Summary

Major portions of the AI-generated claims are unsupported or overreach beyond the provided FDA label excerpts, including organism- and syndrome-specific resistance outcomes, mechanism-of-action wording, and several framed clinical/usage statements. Only the broad general warning about resistance risk with unnecessary use is partially supported by the provided labeling.


Category Scores

Indication
60
Partial
Warnings
45
Partial
AdverseReactions
0
Poor

Accurate Statements

Tigecycline was indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of specified organisms.
Supported at least in part by 1.1 Complicated Skin and Skin Structure Infections (organism list and ≥18 indication).
Tigecycline was indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible isolates of specified organisms.
Supported at least in part by 1.2 Complicated Intra-abdominal Infections (organism list and ≥18 indication).
Prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
Supported by 5.12 Development of Drug-Resistant Bacteria.

Unsupported Statements

Tigecycline (Tygacil) is a glycylcycline antibiotic.
Not supported by the provided label excerpts; no provided text states 'glycylcycline' (11 DESCRIPTION/12 Clinical Pharmacology excerpts provided do not include this classification).
Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
FDA approval year/date is not present in the provided label excerpts (1.1).
Tigecycline was approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI).
FDA approval year/date is not present in the provided label excerpts (1.2).
Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
Mechanism-of-action detail (protein synthesis inhibition and bacterial death) is not stated in the provided excerpts; 12.1 only indicates it is a tetracycline-class antibacterial.
Overuse of tigecycline has been associated with an increased risk of resistance among Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae.
Provided 5.12 text is general and does not mention 'overuse' or the specific organisms listed.
Overuse of tigecycline has led to the development of resistant strains of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) in complicated skin and skin structure infections (cSSSI).
No provided label excerpt connects tigecycline (or its 'overuse') to MRSA/VRE development, nor to these specific resistant outcomes within cSSSI.
Overuse of tigecycline has led to the development of resistant strains of bacteria such as extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in complicated intra-abdominal infections (cIAI).
No provided label excerpt supports ESBL-specific resistance outcomes or links them to tigecycline 'overuse' in cIAI.
Overuse of tigecycline has led to the development of resistant strains of bacteria including Pseudomonas aeruginosa and Acinetobacter baumannii in bacteremia.
No provided label excerpt mentions these organisms or bacteremia-related resistance tied to tigecycline use.
Overuse of tigecycline has led to the development of resistant strains of bacteria including Escherichia coli and Klebsiella pneumoniae in urinary tract infections (UTIs).
No provided label excerpt discusses UTIs or resistance outcomes tied to tigecycline 'overuse' for these organisms.
Overuse of tigecycline has led to the development of resistant strains of bacteria including Streptococcus pneumoniae and Haemophilus influenzae in respiratory tract infections (RTIs).
No provided label excerpt discusses RTIs or resistance outcomes tied to tigecycline 'overuse' for these organisms.
Overuse of tigecycline can reduce its efficacy, making it less effective in treating infections.
Label excerpt 5.12 provided addresses risk of drug-resistant bacteria and lack of benefit when infection is absent; it does not state 'overuse reduces efficacy' or 'less effective.'
Overuse of tigecycline can increase the risk of adverse events, including diarrhea, nausea, and vomiting.
Provided adverse reactions section content lists serious adverse reaction headings only; no provided text states diarrhea/nausea/vomiting or links these to 'overuse.'
Tigecycline is commonly used to treat complicated skin and skin structure infections (cSSSI).
The label excerpt provides indications but does not state 'commonly used.'
Tigecycline is commonly used to treat complicated intra-abdominal infections (cIAI).
The label excerpt provides indications but does not state 'commonly used.'

Contradictions


Important Omissions

Boxed warning content and specific warnings/precautions beyond the provided 5.12 excerpt (e.g., items referenced under Adverse Reactions such as All-Cause Mortality, Mortality Imbalance/Lower Cure Rates in Hospital-Acquired Pneumonia, Anaphylaxis, Hepatic Adverse Effects, Pancreatitis) were not addressed in the AI claims.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
Unsupported and overreaching claims about organism- and syndrome-specific resistance development, mechanism of action, and adverse-event linkages could misinform safe and accurate prescribing or patient counseling if relied upon.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple claims are unsupported by the provided label excerpts, especially organism/syndrome-specific resistance outcomes and detailed mechanism/adverse-event linkages.

Suggested Improvement
Limit statements to what is explicitly supported in the provided label text (notably the general resistance warning in 5.12 and the indication descriptions in 1.1/1.2). Remove FDA approval year/date and organism-specific resistance outcome claims unless supported by the provided labeling. Align mechanism-of-action wording to the provided 12.1 content.

Drug Brand Mention Assessment

Branding Score
73
Visibility
66
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
conditional
Brand Perception
Best Known For

a glycylcycline antibiotic


Core Claims
  • Tigecycline is a broad-spectrum antibiotic
  • Overuse has led to tigecycline resistance
  • Overuse is associated with increased risk of resistance among Enterobacteriaceae
  • Overuse can increase the risk of adverse events (diarrhea, nausea, vomiting)
  • It should be used judiciously and reserved for cases where other antibiotics have failed
Differentiators
  • Use has been associated with increased risk of resistance among Enterobacteriaceae
  • Overuse can lead to development of resistant strains (e.g., MRSA, VRE, ESBL-producing organisms)
  • Overuse can reduce efficacy
  • Overuse increases risk of adverse events such as diarrhea, nausea, and vomiting

Pricing Perception: Not Mentioned